Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study

Kahan, Z.Gil-Gil, M.Ruiz-Borrego, M.Carrasco, E. M.Ciruelos, E. M.Munoz, M.Bermejo De Las Heras, B.Margeli Vila, M.Anton, A.Casas, M.Calvo, L.de la Haba, J.Ramos, M.Alvarez-Lopez, I.Gal-Yam, E.Gautier, E.Corsaro, M.Rodrigalvarez, G.Zielinski, C.Martin Jimenez, M.2025-01-072025-01-072020-05-010923-7534https://hdl.handle.net/10668/25935enQuality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL studyconference outputopen access10.1016/j.annonc.2020.03.2441569-8041http://www.annalsofoncology.org/article/S0923753420363237/pdf538879300127